Impact of High-Pillow Sleeping Posture on Intraocular Pressure in Glaucoma
January 28, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
MT-1303
Class :
Immunomodulatory agents
Brand Name :
N/A
Synonyms :
MT-1303
Class :
Immunomodulatory agents
Dosage Forms & Strengths
Capsule
0.1mg
0.2mg
0.4mg
0.2 - 0.4
mg
Orally
Off-label as per clinical study
0.1 - 0.4
mg
Orally
once a day
Off-label as per clinical study
Systemic Lupus Erythematosus (SLE)
0.2 - 0.4
mg
Orally
Off-label as per clinical study
Dosage Forms & Strengths
Safety and efficacy data are not studied
Refer to adult dosing
Actions and Spectrum
Actions and spectrum:
Actions: Amiselimod phosphate specifically modulates the sphingosine 1-phosphate receptor.
Spectrum: This might treat autoimmune, inflammatory, multiple sclerosis, and colitis.
Frequency not defined
Decreased count of lymphocytes
Headache
Cold
Hemorrhoids
Nausea
Stomatitis
Diarrhea
Reduced weight
Discomfort in chest
Pain in the upper abdomen
Frequency defined
Nasopharyngitis (23.5%)
Infections of the upper respiratory tract
Black Box Warning
No special black box warnings are available for this drug
Contraindication/Caution:
Contraindication:
Hypersensitivity
Caution:
Diabetes Miletus
Pregnancy
Basal cell carcinoma
Pregnancy/Lactation
Pregnancy consideration:
USFDA pregnancy category: Not assigned
Lactation:
Safety and efficacy study is not established
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Amiselimod phosphate is an immunomodulatory drug currently in phase 3 of clinical trials
Pharmacodynamics:
It is a novel modulator of S1P1 (sphingosine 1-phosphate receptor-1), which is designed to possess less bradycardic effects due to various S1P receptor modulators and fingolimod
Pharmacokinetics:
Data on how it’s absorbed and distribution with amiselimod phosphate are not available.
Metabolism
Amiselimod phosphate passes hepatic metabolism.
Elimination and excretion
This drug is being studied due to its non-renal elimination mechanism. About 0.05% of the recommended medication is eliminated in urine.
Half-life:
404 hours
Administration:
Amiselimod phosphate should be taken oral before or after eating.
Patient information leaflet
Generic Name: amiselimod phosphate
Why do we use amiselimod phosphate?
Amiselimod phosphate as a new immunomodulatory drug now in phase 2 clinical studies. The medicine is being researched for its effectiveness in treating ulcerative colitis, multiple sclerosis, bowel inflammation, systemic lupus erythematosus.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
